A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients

Hiram C. Polk, William G. Cheadle, David H. Livingston, Jorge L. Rodriguez, Karen M. Starko, Allen E. Izu, Howard S. Jaffe, Gerald Sonnenfeld

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Many aspects of the normal immune response are depressed after severe injury. Reduced monocyte human leukocyte antigen-DR (HLA-DR) levels have closely correlated with the development of major infection. After a pilot study with recombinant interferon-γ (rIFN-γ) showed restoration of depressed HLA-DR levels after major injury, a multicenter, prospective, randomized, double-blind trial was conducted. Two hundred thirteen trauma patients who were at high risk of infection received either placebo or rIFN-γ (100 μg) subcutaneously each day for 10 days after admission. One hundred ninety-three patients were evaluable with respect to primary end points. Patients treated with rIFN-γ were older (p = 0.10) and had more severe modes of injury (p = 0.02). By the third day, both monocyte HLA-DR antigen expression and outcome predictive score were significantly better in the rIFN-γ-treated group than in the placebo group (p = 0.0001 and p = 0.0006, respectively). Nine deaths occurred in patients treated with rIFN-γ compared with 12 deaths in the placebo group (p = 0.46). Major infections requiring surgical drainage or dé-bridement occurred in 17 patients treated with rIFN-γ compared with 22 treated with placebo. No difference between treatment arms was noted in overall major or minor infection rates, but there were fewer severe infections that required reoperation or computer tomographic-guided drainage in patients receiving IFN-γ. While these results suggest that rIFN-γ may be useful in some aspects of infection in the patient with severe trauma, a larger trial with longer treatment will be needed to prove the comprehensive value of rIFN-γ.

Original languageEnglish (US)
Pages (from-to)191-196
Number of pages6
JournalThe American Journal of Surgery
Volume163
Issue number2
DOIs
StatePublished - Feb 1992

Fingerprint

Interferons
Randomized Controlled Trials
HLA Antigens
Infection
Placebos
Wounds and Injuries
Monocytes
Drainage
Reoperation
Antigens
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Polk, Hiram C. ; Cheadle, William G. ; Livingston, David H. ; Rodriguez, Jorge L. ; Starko, Karen M. ; Izu, Allen E. ; Jaffe, Howard S. ; Sonnenfeld, Gerald. / A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients. In: The American Journal of Surgery. 1992 ; Vol. 163, No. 2. pp. 191-196.
@article{42d7b0ddc1d94e18abb5162fdc0a1b48,
title = "A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients",
abstract = "Many aspects of the normal immune response are depressed after severe injury. Reduced monocyte human leukocyte antigen-DR (HLA-DR) levels have closely correlated with the development of major infection. After a pilot study with recombinant interferon-γ (rIFN-γ) showed restoration of depressed HLA-DR levels after major injury, a multicenter, prospective, randomized, double-blind trial was conducted. Two hundred thirteen trauma patients who were at high risk of infection received either placebo or rIFN-γ (100 μg) subcutaneously each day for 10 days after admission. One hundred ninety-three patients were evaluable with respect to primary end points. Patients treated with rIFN-γ were older (p = 0.10) and had more severe modes of injury (p = 0.02). By the third day, both monocyte HLA-DR antigen expression and outcome predictive score were significantly better in the rIFN-γ-treated group than in the placebo group (p = 0.0001 and p = 0.0006, respectively). Nine deaths occurred in patients treated with rIFN-γ compared with 12 deaths in the placebo group (p = 0.46). Major infections requiring surgical drainage or d{\'e}-bridement occurred in 17 patients treated with rIFN-γ compared with 22 treated with placebo. No difference between treatment arms was noted in overall major or minor infection rates, but there were fewer severe infections that required reoperation or computer tomographic-guided drainage in patients receiving IFN-γ. While these results suggest that rIFN-γ may be useful in some aspects of infection in the patient with severe trauma, a larger trial with longer treatment will be needed to prove the comprehensive value of rIFN-γ.",
author = "Polk, {Hiram C.} and Cheadle, {William G.} and Livingston, {David H.} and Rodriguez, {Jorge L.} and Starko, {Karen M.} and Izu, {Allen E.} and Jaffe, {Howard S.} and Gerald Sonnenfeld",
year = "1992",
month = "2",
doi = "10.1016/0002-9610(92)90099-D",
language = "English (US)",
volume = "163",
pages = "191--196",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "2",

}

A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients. / Polk, Hiram C.; Cheadle, William G.; Livingston, David H.; Rodriguez, Jorge L.; Starko, Karen M.; Izu, Allen E.; Jaffe, Howard S.; Sonnenfeld, Gerald.

In: The American Journal of Surgery, Vol. 163, No. 2, 02.1992, p. 191-196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients

AU - Polk, Hiram C.

AU - Cheadle, William G.

AU - Livingston, David H.

AU - Rodriguez, Jorge L.

AU - Starko, Karen M.

AU - Izu, Allen E.

AU - Jaffe, Howard S.

AU - Sonnenfeld, Gerald

PY - 1992/2

Y1 - 1992/2

N2 - Many aspects of the normal immune response are depressed after severe injury. Reduced monocyte human leukocyte antigen-DR (HLA-DR) levels have closely correlated with the development of major infection. After a pilot study with recombinant interferon-γ (rIFN-γ) showed restoration of depressed HLA-DR levels after major injury, a multicenter, prospective, randomized, double-blind trial was conducted. Two hundred thirteen trauma patients who were at high risk of infection received either placebo or rIFN-γ (100 μg) subcutaneously each day for 10 days after admission. One hundred ninety-three patients were evaluable with respect to primary end points. Patients treated with rIFN-γ were older (p = 0.10) and had more severe modes of injury (p = 0.02). By the third day, both monocyte HLA-DR antigen expression and outcome predictive score were significantly better in the rIFN-γ-treated group than in the placebo group (p = 0.0001 and p = 0.0006, respectively). Nine deaths occurred in patients treated with rIFN-γ compared with 12 deaths in the placebo group (p = 0.46). Major infections requiring surgical drainage or dé-bridement occurred in 17 patients treated with rIFN-γ compared with 22 treated with placebo. No difference between treatment arms was noted in overall major or minor infection rates, but there were fewer severe infections that required reoperation or computer tomographic-guided drainage in patients receiving IFN-γ. While these results suggest that rIFN-γ may be useful in some aspects of infection in the patient with severe trauma, a larger trial with longer treatment will be needed to prove the comprehensive value of rIFN-γ.

AB - Many aspects of the normal immune response are depressed after severe injury. Reduced monocyte human leukocyte antigen-DR (HLA-DR) levels have closely correlated with the development of major infection. After a pilot study with recombinant interferon-γ (rIFN-γ) showed restoration of depressed HLA-DR levels after major injury, a multicenter, prospective, randomized, double-blind trial was conducted. Two hundred thirteen trauma patients who were at high risk of infection received either placebo or rIFN-γ (100 μg) subcutaneously each day for 10 days after admission. One hundred ninety-three patients were evaluable with respect to primary end points. Patients treated with rIFN-γ were older (p = 0.10) and had more severe modes of injury (p = 0.02). By the third day, both monocyte HLA-DR antigen expression and outcome predictive score were significantly better in the rIFN-γ-treated group than in the placebo group (p = 0.0001 and p = 0.0006, respectively). Nine deaths occurred in patients treated with rIFN-γ compared with 12 deaths in the placebo group (p = 0.46). Major infections requiring surgical drainage or dé-bridement occurred in 17 patients treated with rIFN-γ compared with 22 treated with placebo. No difference between treatment arms was noted in overall major or minor infection rates, but there were fewer severe infections that required reoperation or computer tomographic-guided drainage in patients receiving IFN-γ. While these results suggest that rIFN-γ may be useful in some aspects of infection in the patient with severe trauma, a larger trial with longer treatment will be needed to prove the comprehensive value of rIFN-γ.

UR - http://www.scopus.com/inward/record.url?scp=0027055454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027055454&partnerID=8YFLogxK

U2 - 10.1016/0002-9610(92)90099-D

DO - 10.1016/0002-9610(92)90099-D

M3 - Article

C2 - 1739172

AN - SCOPUS:0027055454

VL - 163

SP - 191

EP - 196

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 2

ER -